<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307435</url>
  </required_header>
  <id_info>
    <org_study_id>ISMMSC001</org_study_id>
    <nct_id>NCT02307435</nct_id>
  </id_info>
  <brief_title>Allogenic Mesenchymal Stem Cell for Bone Defect or Non Union Fracture</brief_title>
  <acronym>AMSC</acronym>
  <official_title>Potency of Allogenic Bone Marrow, Umbilical Cord, Adipose Mesenchymal Stem Cell for Non Union Fracture and Long Bone Defect, Directly and Cryopreserved</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mesenchymal stem cell (MSC) is one kind of stem cell which is gained form adult tissue.
      Although MSC derived from autogenic bone marrow are proven to help regeneration in non union
      fracture and long bone defect, the aspiration process through iliac crest is invasive and
      painful.

      Therefore, alternative source of MSC which is less invasive is needed. Adipose and umbilical
      cord is a &quot;waste product&quot; that proven to contain enormous MSC. Furthermore adipose and
      umbilical cord as an allogenic source is more abundant in number compares to autogenic bone
      marrow. This enormous source need and adequate preservation technique before applied to the
      patient. According to that, researchers want to explore the potency of MSC from bone marrow,
      umbilical cord and adipose as the source of allogenic MSC and the effect of cryopreservation
      technique to the viability and quality of MSC. We will also compare the effectivity of MSC
      implantation from bone marrow, umbilical cord and adipose applied to non union fracture and
      long bone defect.

      Samples from bone marrow, umbilical cord and adipose are cultured and the viability of the
      cells are observed. Some of the cells are implanted directly to the patient with non union
      fractures and long bone defect while some are cryopreserved in liquid nitrogen -190 degree
      Celsius in three months. All samples are thawed and the viability of the cells are observed.
      Patient who are implanted by MSC allogenic will undergo clinical and radiological examination
      in the third, sixth and twenty second month after implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Methods Study Design This study is an experimental one arm study post test only.
      Estimated Study Time Research estimated time would be 24 months, from May 2014 to May 2016.
      Sample Gaining Procedure This research is a pilot study. Samples are obtained consecutively
      from all source population that meet the criteria. The number of samples from each
      mesenchymal stem cell ( adipose, bone marrow and umbilical cord) source are three. Each
      samples derived from three different donors that met the inclusion criteria. For the
      implanation, the subjects are five from each intervention. Yet regarding the limited funding
      source and time, we will recruit one subject for each kind of MSC.

      Subject Criteria Inclusion criteria for MSC donor

      Bone marrow donor :

      Male/female aged 19-30 year without any comorbiditites (Diabetes mellitus, cardiovascular and
      any other autoimmune disease), HIV test Hepatitis B test and Hepatitis C test are negaitve,
      no fungal and bacterial contamination in the bone marrow. Subjects are willing to be
      aspiratied in the iliac crest in order to get the bone marrow.

      Adipose donor :

      Adipose tissue are gained from liposuction or open reduction internal fixation procedure.
      Samples of adipose are free from HIV, Hepatitis B, Hepatitis C and free from fungal and
      bacterial contamination.

      Umbilical cord donor :

      Umbilical cord are form elective seccio caecaria from a fullterm mother without any
      complications and free from HIV, hepatitis B, hepatitis C and no fungal and bacterial
      contamination.

      Recipient inclusion criteria Critical bone defect patients aged 6-55 who are willing to
      undergo surgical intervention.

      Recipient exclusion criteria Patients with pathological fracture caused by malignancy,
      immunocompromised ( HIV AIDS, Diabetes mellitus, active Hepatitis), in a immunosuppresant
      therapy ( chemotherapy or steroids).

      Drop out criteria Patients are ruled out from this study if he/she stated to do so in the
      time this research are held or she/he undergoes any other threatment that are not related to
      this study. Patient who does not show any clinical improvement in three consecutive months is
      categorized as failed to threat. All drop out and failed to threat patient could get other
      threatment.

      Informed Consent All subjects must fill and sign in the informed consent letters.

      Research Protocol Mesenchymal stem cell taking method Bone Marrow taking Patient is lying
      down in supine position, anesthetized locally. Aseptic and antiseptic are done in the illiac
      crest location. Aspiration needle is inserted 450 to horizon in illiac crest. Hub is released
      and a 10 cc syringe that contain heparin is connected to te needle. We aspirated about 50 cc
      bone marrow from each subject.

      Umbilical cord taking Right after the delivering the baby, the umbilical cord are cut and
      kept in a sterile bowl containing 0.9% NaCl in 40 until the sample is proceed.

      Adipose taking Adipose tissue are derived from liposuction or open reduction internal
      fixation procedure. It is kept in a sterile bowl containing NaCL 0.9% in 40 C. Processing of
      the sample is done within 8 hours after sample are taken.

      Cryopreservation and re activation. All the samples are taken to culture laboratory in
      integrated service of stem cell medical technology Cipto mangunkusumo hospita.this laboratory
      is GMP (good manufacturing Product) certified. The samples ate cultured in appropriated
      medium until it reach confluence and harvested. The cells then undergo caracterisation test
      by flow cyto meter and viability and numbers are counted. Some of the cells then
      cryopreserved while some are directly implanted into patient. The cells are cryopreserved for
      three months and then reactivated. Viability and numbers then are measured. The cells then
      are implanted to non union patient.

      Specimen sterility Sterility tests are done three times to ensure there is no fungal and
      bacterial contamination.

      HA-CaSO4 and MSC For every centimeter of defect, 10 millions cells and 50 pellet HA-CaSO4 are
      needed. The diluted MSC then mix with the HA-CaSO4 and incubated 5 minutes before implanted.

      Intervention Surgical intervention is needed to assemble the fixation device in the long
      bone. During the surgery, pellet HA-CaSO4 are inserted into the defect. After soft tissue are
      closed the rest of the serum is injected into the defect area.

      Observation and follow up Clinical and radiological follow up is done every 4 weeks.
      Observation is done for 12 months or untill the bone unites. Every subject will be followed
      up in the third, sixth, twelfth and twenty forth or until the fixation device is taken off.

      Recipient criteria for non union fracture
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cell viability</measure>
    <time_frame>3 months</time_frame>
    <description>percentage of cells that live divided by total cell</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lower extremity functional score</measure>
    <time_frame>3 months</time_frame>
    <description>lower extremities functional score sheet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disabilities of arm shoulder and hand</measure>
    <time_frame>3 months</time_frame>
    <description>disabilities of arm shoulder and hand score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Non Union Fracture</condition>
  <condition>Metaphyseal Fibrous Defect</condition>
  <arm_group>
    <arm_group_label>implantation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>implantation group will receive MSC and HA-CaSo4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC</intervention_name>
    <description>subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose</description>
    <arm_group_label>implantation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for MSC donor

          -  Bone marrow donor : Male/female aged 19-30 year without any comorbiditites (Diabetes
             mellitus, cardiovascular and any other autoimmune disease),HIV test Hepatitis B test
             and Hepatitis C test are negaitve, no fungal and bacterial contamination in the bone
             marrow. Subjects are willing to be aspiratied in the iliac crest in order to get the
             bone marrow.

          -  Adipose donor : Adipose tissue are gained from liposuction or open reduction internal
             fixation procedure. Samples of adipose are free from HIV, Hepatitis B, Hepatitis C and
             free from fungal and bacterial contamination.

          -  Umbilical cord donor : Umbilical cord are form elective seccio caecaria from a
             fullterm mother without any complications and free from HIV, hepatitis B, hepatitis C
             and no fungal and bacterial contamination.

        exclusion / Drop out criteria

        -Patients are ruled out from this study if he/she stated to do so in the time this research
        are held or she/he undergoes any other threatment that are not related to this study.
        Patient who does not show any clinical improvement in three consecutive months is
        categorized as failed to threat. All drop out and failed to threat patient could get other
        threatment.

        inclusion criteria for recipient : -male/female aged 6-55 year old with bone critical
        defect

        exclusion criteria for recipient :

        -Patients with pathological fracture caused by malignancy, immunocompromised ( HIV AIDS,
        Diabetes mellitus, active Hepatitis), in a immunosuppresant therapy ( chemotherapy or
        steroids).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ISMAIL H DILOGO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>integrated unit of stem cell and medical technology CIPTO MANGUNKUSUMO GENERAL HOSPITAL, FACULTY OF MEDICINE UNIVERSITI OF INDONESIA, INDONESIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ismail h dilogo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ISMAIL H DILOGO, MD, SPOT</last_name>
    <phone>+6221 44539917</phone>
    <email>ISMAILORTHOFKUI@YAHOO.CO.ID</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PRIMA R OKTARI, MD</last_name>
    <phone>+6281238107568</phone>
    <email>PRIMARIZKYOKTARI@GMAIL.COM</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Indonesia</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TRI KURNIAWATI, BSc</last_name>
      <phone>+6221 44539917</phone>
      <email>SELPUNCARSCM@YAHOO.CO.ID</email>
    </contact>
    <contact_backup>
      <last_name>PRIMA R OKTARI, MD</last_name>
      <phone>+6281238107568</phone>
      <email>PRIMARIZKYOKTARI@GMAIL.COM</email>
    </contact_backup>
    <investigator>
      <last_name>ISMAIL H DILOGO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, University of Indonesia</name>
      <address>
        <city>Propinsi DKI Jakarta</city>
        <state>Jakarta</state>
        <zip>16424</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ISMAIL H DILOGO, MD</last_name>
      <phone>+628129499428</phone>
      <email>ISMAILORTHO@GMAIL.COM</email>
    </contact>
    <contact_backup>
      <last_name>PRIMA R OKTARI, MD</last_name>
      <phone>+6281238107568</phone>
      <email>PRIMARIZKYOKTARI@GMAIL.COM</email>
    </contact_backup>
    <investigator>
      <last_name>ISMAIL H DILOGO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Kon E, Muraglia A, Corsi A, Bianco P, Marcacci M, Martin I, Boyde A, Ruspantini I, Chistolini P, Rocca M, Giardino R, Cancedda R, Quarto R. Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones. J Biomed Mater Res. 2000 Mar 5;49(3):328-37.</citation>
    <PMID>10602065</PMID>
  </reference>
  <reference>
    <citation>Hee HT, Ismail HD, Lim CT, Goh JC, Wong HK. Effects of implantation of bone marrow mesenchymal stem cells, disc distraction and combined therapy on reversing degeneration of the intervertebral disc. J Bone Joint Surg Br. 2010 May;92(5):726-36. doi: 10.1302/0301-620X.92B5.23015.</citation>
    <PMID>20436013</PMID>
  </reference>
  <reference>
    <citation>Ye Z, Wang Y, Xie HY, Zheng SS. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4+CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int. 2008 Dec;7(6):608-14.</citation>
    <PMID>19073406</PMID>
  </reference>
  <reference>
    <citation>Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, Pistoia V, Martin I, Tyndall A. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford). 2007 Mar;46(3):403-8. Epub 2006 Aug 18.</citation>
    <PMID>16920750</PMID>
  </reference>
  <reference>
    <citation>Yañez R, Lamana ML, García-Castro J, Colmenero I, Ramírez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006 Nov;24(11):2582-91. Epub 2006 Jul 27.</citation>
    <PMID>16873762</PMID>
  </reference>
  <reference>
    <citation>Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol. 2010 Nov-Dec;88(8):795-806. doi: 10.1038/icb.2010.47. Epub 2010 Apr 13.</citation>
    <PMID>20386557</PMID>
  </reference>
  <results_reference>
    <citation>Hou ZL, Liu Y, Mao XH, Wei CY, Meng MY, Liu YH, Zhuyun Yang Z, Zhu H, Short M, Bernard C, Xiao ZC. Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis. Cell Adh Migr. 2013 Sep-Oct;7(5):404-7. doi: 10.4161/cam.26941. Epub 2013 Oct 30.</citation>
    <PMID>24192520</PMID>
  </results_reference>
  <results_reference>
    <citation>Brinker MR, O'Connor DP. The incidence of fractures and dislocations referred for orthopaedic services in a capitated population. J Bone Joint Surg Am. 2004 Feb;86-A(2):290-7.</citation>
    <PMID>14960673</PMID>
  </results_reference>
  <results_reference>
    <citation>Liebergall M, Schroeder J, Mosheiff R, Gazit Z, Yoram Z, Rasooly L, Daskal A, Khoury A, Weil Y, Beyth S. Stem cell-based therapy for prevention of delayed fracture union: a randomized and prospective preliminary study. Mol Ther. 2013 Aug;21(8):1631-8. doi: 10.1038/mt.2013.109. Epub 2013 Jun 4.</citation>
    <PMID>23732992</PMID>
  </results_reference>
  <results_reference>
    <citation>Sen MK, Miclau T. Autologous iliac crest bone graft: should it still be the gold standard for treating nonunions? Injury. 2007 Mar;38 Suppl 1:S75-80. Review.</citation>
    <PMID>17383488</PMID>
  </results_reference>
  <results_reference>
    <citation>Goulet JA, Senunas LE, DeSilva GL, Greenfield ML. Autogenous iliac crest bone graft. Complications and functional assessment. Clin Orthop Relat Res. 1997 Jun;(339):76-81.</citation>
    <PMID>9186204</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauney JR, Volloch V, Kaplan DL. Role of adult mesenchymal stem cells in bone tissue engineering applications: current status and future prospects. Tissue Eng. 2005 May-Jun;11(5-6):787-802. Review.</citation>
    <PMID>15998219</PMID>
  </results_reference>
  <results_reference>
    <citation>Cavallo C, Cuomo C, Fantini S, Ricci F, Tazzari PL, Lucarelli E, Donati D, Facchini A, Lisignoli G, Fornasari PM, Grigolo B, Moroni L. Comparison of alternative mesenchymal stem cell sources for cell banking and musculoskeletal advanced therapies. J Cell Biochem. 2011 May;112(5):1418-30. doi: 10.1002/jcb.23058.</citation>
    <PMID>21321995</PMID>
  </results_reference>
  <results_reference>
    <citation>Jurgens WJ, Oedayrajsingh-Varma MJ, Helder MN, Zandiehdoulabi B, Schouten TE, Kuik DJ, Ritt MJ, van Milligen FJ. Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies. Cell Tissue Res. 2008 Jun;332(3):415-26. doi: 10.1007/s00441-007-0555-7. Epub 2008 Apr 1.</citation>
    <PMID>18379826</PMID>
  </results_reference>
  <results_reference>
    <citation>Lu Z, Wang G, Dunstan CR, Chen Y, Lu WY, Davies B, Zreiqat H. Activation and promotion of adipose stem cells by tumour necrosis factor-α preconditioning for bone regeneration. J Cell Physiol. 2013 Aug;228(8):1737-44. doi: 10.1002/jcp.24330.</citation>
    <PMID>23359411</PMID>
  </results_reference>
  <results_reference>
    <citation>Parolini O, Alviano F, Bagnara GP, Bilic G, Bühring HJ, Evangelista M, Hennerbichler S, Liu B, Magatti M, Mao N, Miki T, Marongiu F, Nakajima H, Nikaido T, Portmann-Lanz CB, Sankar V, Soncini M, Stadler G, Surbek D, Takahashi TA, Redl H, Sakuragawa N, Wolbank S, Zeisberger S, Zisch A, Strom SC. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells. 2008 Feb;26(2):300-11. Epub 2007 Nov 1. Review.</citation>
    <PMID>17975221</PMID>
  </results_reference>
  <results_reference>
    <citation>Troyer DL, Weiss ML. Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells. 2008 Mar;26(3):591-9. Epub 2007 Dec 6. Review.</citation>
    <PMID>18065397</PMID>
  </results_reference>
  <results_reference>
    <citation>Bernardo ME, Emons JA, Karperien M, Nauta AJ, Willemze R, Roelofs H, Romeo S, Marchini A, Rappold GA, Vukicevic S, Locatelli F, Fibbe WE. Human mesenchymal stem cells derived from bone marrow display a better chondrogenic differentiation compared with other sources. Connect Tissue Res. 2007;48(3):132-40.</citation>
    <PMID>17522996</PMID>
  </results_reference>
  <results_reference>
    <citation>Im GI, Shin YW, Lee KB. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? Osteoarthritis Cartilage. 2005 Oct;13(10):845-53.</citation>
    <PMID>16129630</PMID>
  </results_reference>
  <results_reference>
    <citation>Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, Kim SW, Yang YS, Oh W, Chang JW. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci. 2013 Sep 3;14(9):17986-8001. doi: 10.3390/ijms140917986.</citation>
    <PMID>24005862</PMID>
  </results_reference>
  <results_reference>
    <citation>Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006 May;24(5):1294-301. Epub 2006 Jan 12.</citation>
    <PMID>16410387</PMID>
  </results_reference>
  <results_reference>
    <citation>Miao Z, Jin J, Chen L, Zhu J, Huang W, Zhao J, Qian H, Zhang X. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol Int. 2006 Sep;30(9):681-7. Epub 2006 Apr 22.</citation>
    <PMID>16870478</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu L, Hu J, Zhao J, Liu J, Ouyang W, Yang C, Gong N, Du L, Khanal A, Chen L. Side-by-side comparison of the biological characteristics of human umbilical cord and adipose tissue-derived mesenchymal stem cells. Biomed Res Int. 2013;2013:438243. doi: 10.1155/2013/438243. Epub 2013 Jul 7.</citation>
    <PMID>23936800</PMID>
  </results_reference>
  <results_reference>
    <citation>Toupadakis CA, Wong A, Genetos DC, Cheung WK, Borjesson DL, Ferraro GL, Galuppo LD, Leach JK, Owens SD, Yellowley CE. Comparison of the osteogenic potential of equine mesenchymal stem cells from bone marrow, adipose tissue, umbilical cord blood, and umbilical cord tissue. Am J Vet Res. 2010 Oct;71(10):1237-45. doi: 10.2460/ajvr.71.10.1237.</citation>
    <PMID>20919913</PMID>
  </results_reference>
  <results_reference>
    <citation>Shafiee A, Seyedjafari E, Soleimani M, Ahmadbeigi N, Dinarvand P, Ghaemi N. A comparison between osteogenic differentiation of human unrestricted somatic stem cells and mesenchymal stem cells from bone marrow and adipose tissue. Biotechnol Lett. 2011 Jun;33(6):1257-64. doi: 10.1007/s10529-011-0541-8. Epub 2011 Feb 2.</citation>
    <PMID>21287233</PMID>
  </results_reference>
  <results_reference>
    <citation>Arinzeh TL, Peter SJ, Archambault MP, van den Bos C, Gordon S, Kraus K, Smith A, Kadiyala S. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am. 2003 Oct;85-A(10):1927-35.</citation>
    <PMID>14563800</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruder SP, Kraus KH, Goldberg VM, Kadiyala S. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. J Bone Joint Surg Am. 1998 Jul;80(7):985-96.</citation>
    <PMID>9698003</PMID>
  </results_reference>
  <results_reference>
    <citation>Viateau V, Guillemin G, Bousson V, Oudina K, Hannouche D, Sedel L, Logeart-Avramoglou D, Petite H. Long-bone critical-size defects treated with tissue-engineered grafts: a study on sheep. J Orthop Res. 2007 Jun;25(6):741-9.</citation>
    <PMID>17318898</PMID>
  </results_reference>
  <results_reference>
    <citation>Schubert T, Lafont S, Beaurin G, Grisay G, Behets C, Gianello P, Dufrane D. Critical size bone defect reconstruction by an autologous 3D osteogenic-like tissue derived from differentiated adipose MSCs. Biomaterials. 2013 Jun;34(18):4428-38. doi: 10.1016/j.biomaterials.2013.02.053. Epub 2013 Mar 16.</citation>
    <PMID>23507085</PMID>
  </results_reference>
  <results_reference>
    <citation>Shoji T, Ii M, Mifune Y, Matsumoto T, Kawamoto A, Kwon SM, Kuroda T, Kuroda R, Kurosaka M, Asahara T. Local transplantation of human multipotent adipose-derived stem cells accelerates fracture healing via enhanced osteogenesis and angiogenesis. Lab Invest. 2010 Apr;90(4):637-49. doi: 10.1038/labinvest.2010.39. Epub 2010 Feb 15.</citation>
    <PMID>20157290</PMID>
  </results_reference>
  <results_reference>
    <citation>Thirumala S, Goebel WS, Woods EJ. Clinical grade adult stem cell banking. Organogenesis. 2009 Jul;5(3):143-54.</citation>
    <PMID>20046678</PMID>
  </results_reference>
  <results_reference>
    <citation>Matsumura K, Hayashi F, Nagashima T, Hyon SH. Long-term cryopreservation of human mesenchymal stem cells using carboxylated poly-l-lysine without the addition of proteins or dimethyl sulfoxide. J Biomater Sci Polym Ed. 2013;24(12):1484-97. doi: 10.1080/09205063.2013.771318. Epub 2013 Feb 22.</citation>
    <PMID>23829460</PMID>
  </results_reference>
  <results_reference>
    <citation>Dariolli R, Bassaneze V, Nakamuta JS, Omae SV, Campos LC, Krieger JE. Porcine adipose tissue-derived mesenchymal stem cells retain their proliferative characteristics, senescence, karyotype and plasticity after long-term cryopreservation. PLoS One. 2013 Jul 9;8(7):e67939. doi: 10.1371/journal.pone.0067939. Print 2013.</citation>
    <PMID>23874472</PMID>
  </results_reference>
  <results_reference>
    <citation>Angelo PC, Ferreira AC, Fonseca VD, Frade SP, Ferreira CS, Malta FS, Pereira AK, Leite HV, Brum AP, Pardini VC, Gomes KB, Cabral AC. Cryopreservation does not alter karyotype, multipotency, or NANOG/SOX2 gene expression of amniotic fluid mesenchymal stem cells. Genet Mol Res. 2012 Apr 19;11(2):1002-12. doi: 10.4238/2012.April.19.5.</citation>
    <PMID>22576926</PMID>
  </results_reference>
  <results_reference>
    <citation>Park M, Seo JJ. Role of HLA in Hematopoietic Stem Cell Transplantation. Bone Marrow Res. 2012;2012:680841. doi: 10.1155/2012/680841. Epub 2012 Oct 2.</citation>
    <PMID>23082252</PMID>
  </results_reference>
  <results_reference>
    <citation>Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143-7.</citation>
    <PMID>10102814</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu LY, Chai JK, Duan HJ, Hou YS, Yin HN, Yu YH, Hu Q, Hao DF, Feng G, Li T, Du JD. [Comparison of different methods for the isolation of human umbilical cord mesenchymal stem cells]. Zhonghua Yi Xue Za Zhi. 2013 Aug 27;93(32):2592-6. Chinese.</citation>
    <PMID>24351605</PMID>
  </results_reference>
  <results_reference>
    <citation>Han ZX, Shi Q, Wang DK, Li D, Lyu M. [Basic biological characteristics of mesenchymal stem cells derived from bone marrow and human umbilical cord]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Oct;21(5):1248-55. doi: 10.7534/j.issn.1009-2137.2013.05.033. Chinese.</citation>
    <PMID>24156444</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>December 1, 2014</last_update_submitted>
  <last_update_submitted_qc>December 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Ismail Hadisoebroto Dilogo</investigator_full_name>
    <investigator_title>orthopaedic medical doctor</investigator_title>
  </responsible_party>
  <keyword>non union fracture</keyword>
  <keyword>bone defect</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>cryopreservation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Ununited</mesh_term>
    <mesh_term>Fibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

